Serum matrix metalloproteinase-9 is a valuable biomarker for identification of abdominal and thoracic aortic aneurysm: a case-control study

Abstract

BackgroundMatrix metalloproteinase-9 (MMP9) has been reported to play a key role in the pathogenesis of aortic aneurysm. However, few studies have assessed serum MMP9 levels in both abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA). In this study, we investigated the serum levels of MMP9 in aortic aneurysm to evaluate its predictive and diagnostic efficacy for AAA and TAA, and explored the association of MMP9 with circulating laboratory markers.MethodsA total of 296 subjects were enrolled, including 105 AAA patients, 79 TAA patients and 112 healthy controls. The levels of serum MMP9 were detected by enzyme-linked immunosorbent assay (ELISA).ResultsCompared to control group, both AAA and TAA patients had higher serum MMP9 levels in the overall comparison and subgroup analysis based on subjects aged<65 years, either male or female, hypertension, non-diabetes and non-hyperlipidemia (all P<0.05). Moreover, MMP9 levels were significantly higher in TAA group than those in AAA group in the total comparison, and this discrepancy was also found in the non-diabetes, non-hyperlipidemia and aortic diameter ≥ 5.5 cm subgroup analysis. Serum MMP9 levels were influenced by age and hypertension. There was a positive association of serum MMP9 with CRP (r = 0.33, P < 0.001) and Hcy (r = 0.199, P = 0.033). Multiple logistic analyses showed that serum MMP9 was an independent risk factor for AAA and TAA. Based on receiver operating characteristic (ROC) analysis, the area under the curve (AUC) of MMP9 for predicting TAA was 0.83 with 70% sensitivity and 91% specificity, while the AUC of MMP9 to detect AAA was 0.69 and the sensitivity and specificity were 50% and 88%.ConclusionsSerum MMP9 was closely related to the existence of aortic aneurysms and could be a valuable marker for the discrimination of aortic aneurysm, especially for TAA.

Discovery of novel biomarkers for atherosclerotic aortic aneurysm through proteomics-based assessment of disease progression

“…ROC analysis showed that NPC2 and IGFBP7 had higher diagnostic ability for TAAA and AAAA than the known AA biomarkers, based on the data shown in Fig. 4 (THBS1) and based on the previously reported data (MMP-9, C-C motif chemokine 20, myosin heavy chain 11, and Galectin-3) [42][43][44][45] . We also analysed the correlation between the blood levels of NPC2, IGFBP7, and THBS1 with those of LDL cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglyceride (TG), and CRP.…”

Network‐based analysis reveals novel gene signatures in the peripheral blood of patients with sporadic nonsyndromic thoracic aortic aneurysm

“…Researchers have shown that matrix metalloproteinases (MMPs) play a critical role in the alteration of the aortic ECM architecture contribution to the aortic wall degeneration (Ikonomidis et al, ). MMP2 (Shen et al, ) and MMP‐9 (Ikonomidis et al, ; Li et al, ) have been identified in the TAA tissue and the plasma impaired integrity of the aortic ECM with the effect of promoting aortic aneurysm development in animal models. Interestingly, the top hub gene of the turquoise module is MMP15 .…”

Plasma Metabolomics Analysis Identifies Abnormal Energy, Lipid, and Amino Acid Metabolism in Abdominal Aortic Aneurysms

“…AAAs are characterized by progressive luminal dilation accompanied by aortic wall inflammation, decreased medial smooth muscle cells, and disruption of the extracellular matrix. Although studies have been conducted on a variety of biologically plausible markers for diagnosis and prediction of disease activity in AAA [ 5 – 7 ], there is still a need for a systematic understanding of biological disturbances associated with the condition. Metabolomics is a high-throughput omics technology that follows on the heels of genomics, transcriptomics, and proteomics, and which can be used to simultaneously measure and study a large number of small molecules (<1000 Da) [ 8 ].…”